Reviewer's report
Title:HBV genotypes and response to tenofovir disoproxil fumarate in
HIV/HBV-coinfected persons
Version:2Date:26 December 2014
Reviewer: mahmoudreza pourkarim
Reviewer's report:
The authors in manuscript entitled “HBV genotypes and response to tenofovir
disoproxil fumarate in HIV/HBV-coinfected persons” investigated the impact of
different HBV genotypes on the antiviral therapy among HIV/HBV coinfected
patients. This manuscript is well structured, written and presents valuable data
and could be worthy in the field of antiviral therapy. However answer to few
comments are necessary to improve the study for publication.
1- There is no trace of evolutionary model which were used in phylogenetic
analysis.
2- Recombination is a part of HBV evolution, have the authors ever checked the
recombination of the studied strains.
3- It is not well explained that how “phylogenetic analysis can not clearly
determine the genotype of HBV (see line 166). Some examples in the result and
more explanation materials and methods are necessary.
4- I did not understand well how determination of HBV subtype could resolve this
problem (see line 192). Also, there is no follow up in result and discussion about
this type of problem and resolving it.
5- If the collection of another serum/plasma sample was necessary, how long
was the interval between the first and the next sample collection date.
6- It should be statistically analyzed that is there any association between the
history of LAM therapy and late response to the TDF?
7- The result of multiple HBV genotype infections should be compared with other
studies (particularly, the frequency should be compared). At least three recent
references are necessary.
Reviewer's report
Title:HBV genotypes and response to tenofovir disoproxil fumarate in
HIV/HBV-coinfected persons
Version:2Date:26 December 2014
Reviewer: mahmoudreza pourkarim
Reviewer's report:
The authors in manuscript entitled “HBV genotypes and response to tenofovir
disoproxil fumarate in HIV/HBV-coinfected persons” investigated the impact of
different HBV genotypes on the antiviral therapy among HIV/HBV coinfected
patients. This manuscript is well structured, written and presents valuable data
and could be worthy in the field of antiviral therapy. However answer to few
comments are necessary to improve the study for publication.
1- There is no trace of evolutionary model which were used in phylogenetic
analysis.
2- Recombination is a part of HBV evolution, have the authors ever checked the
recombination of the studied strains.
3- It is not well explained that how “phylogenetic analysis can not clearly
determine the genotype of HBV (see line 166). Some examples in the result and
more explanation materials and methods are necessary.
4- I did not understand well how determination of HBV subtype could resolve this
problem (see line 192). Also, there is no follow up in result and discussion about
this type of problem and resolving it.
5- If the collection of another serum/plasma sample was necessary, how long
was the interval between the first and the next sample collection date.
6- It should be statistically analyzed that is there any association between the
history of LAM therapy and late response to the TDF?
7- The result of multiple HBV genotype infections should be compared with other
studies (particularly, the frequency should be compared). At least three recent
references are necessary.
Please review this paper.
user
Reviewer's report
Title:HBV genotypes and response to tenofovir disoproxil fumarate in
HIV/HBV-coinfected persons
Version:2Date:26 December 2014
Reviewer: mahmoudreza pourkarim
Reviewer's report:
The authors in manuscript entitled “HBV genotypes and response to tenofovir
disoproxil fumarate in HIV/HBV-coinfected persons” investigated the impact of
different HBV genotypes on the antiviral therapy among HIV/HBV coinfected
patients. This manuscript is well structured, written and presents valuable data
and could be worthy in the field of antiviral therapy. However answer to few
comments are necessary to improve the study for publication.
1- There is no trace of evolutionary model which were used in phylogenetic
analysis.
2- Recombination is a part of HBV evolution, have the authors ever checked the
recombination of the studied strains.
3- It is not well explained that how “phylogenetic analysis can not clearly
determine the genotype of HBV (see line 166). Some examples in the result and
more explanation materials and methods are necessary.
4- I did not understand well how determination of HBV subtype could resolve this
problem (see line 192). Also, there is no follow up in result and discussion about
this type of problem and resolving it.
5- If the collection of another serum/plasma sample was necessary, how long
was the interval between the first and the next sample collection date.
6- It should be statistically analyzed that is there any association between the
history of LAM therapy and late response to the TDF?
7- The result of multiple HBV genotype infections should be compared with other
studies (particularly, the frequency should be compared). At least three recent
references are necessary.
assistant